JP2020189838A - コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法 - Google Patents
コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法 Download PDFInfo
- Publication number
- JP2020189838A JP2020189838A JP2020089133A JP2020089133A JP2020189838A JP 2020189838 A JP2020189838 A JP 2020189838A JP 2020089133 A JP2020089133 A JP 2020089133A JP 2020089133 A JP2020089133 A JP 2020089133A JP 2020189838 A JP2020189838 A JP 2020189838A
- Authority
- JP
- Japan
- Prior art keywords
- chinese herbal
- herbal medicine
- cholesterol
- triacylglycerol
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 192
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 89
- 241000411851 herbal medicine Species 0.000 title claims abstract description 59
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 230000006872 improvement Effects 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000004060 metabolic process Effects 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000009472 formulation Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 130
- 239000008280 blood Substances 0.000 claims abstract description 67
- 210000004369 blood Anatomy 0.000 claims abstract description 67
- 241000405414 Rehmannia Species 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 16
- 230000002159 abnormal effect Effects 0.000 claims abstract description 13
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 13
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 12
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 9
- 244000018694 Sagittaria sinensis Species 0.000 claims abstract description 9
- 235000015909 Sagittaria sinensis Nutrition 0.000 claims abstract description 9
- 239000008103 glucose Substances 0.000 claims abstract description 9
- 239000004615 ingredient Substances 0.000 claims abstract description 8
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 6
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 6
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims abstract description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims abstract description 4
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims abstract description 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 78
- 239000000284 extract Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 210000003494 hepatocyte Anatomy 0.000 claims description 10
- 241000736199 Paeonia Species 0.000 claims description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 230000012202 endocytosis Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 241000723438 Cercidiphyllum japonicum Species 0.000 claims description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 239000012674 herbal formulation Substances 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 239000008609 bushi Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 235000005903 Dioscorea Nutrition 0.000 abstract 1
- 244000281702 Dioscorea villosa Species 0.000 abstract 1
- 235000000504 Dioscorea villosa Nutrition 0.000 abstract 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 235000004879 dioscorea Nutrition 0.000 abstract 1
- 239000008820 moutan cortex Substances 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 77
- 210000004185 liver Anatomy 0.000 description 27
- 240000001008 Dimocarpus longan Species 0.000 description 22
- 235000000235 Euphoria longan Nutrition 0.000 description 22
- 230000037361 pathway Effects 0.000 description 17
- 238000010586 diagram Methods 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 230000037356 lipid metabolism Effects 0.000 description 15
- 230000036267 drug metabolism Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical group CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 13
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 13
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 11
- 210000000579 abdominal fat Anatomy 0.000 description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 8
- 229930091371 Fructose Natural products 0.000 description 8
- 239000005715 Fructose Substances 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 7
- 239000004380 Cholic acid Substances 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 7
- 235000019416 cholic acid Nutrition 0.000 description 7
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 7
- 229960002471 cholic acid Drugs 0.000 description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- -1 troches Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 108010001831 LDL receptors Proteins 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000004141 reverse cholesterol transport Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000010832 independent-sample T-test Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 2
- 102100037458 Dephospho-CoA kinase Human genes 0.000 description 2
- 101000952691 Homo sapiens Dephospho-CoA kinase Proteins 0.000 description 2
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- 235000013291 Alisma plantago aquatica Nutrition 0.000 description 1
- 240000004615 Alisma plantago-aquatica Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091005487 SCARB1 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100037118 Scavenger receptor class B member 1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 101710086958 Tsukushi Proteins 0.000 description 1
- 102100031296 Tsukushi Human genes 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 235000019137 high fructose diet Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
表1は、上記結果データの校正後の記述統計表である。表1では、群別比率により記述統計分析を行っている。群別の比率は等しい、同比率(期待臓器重量群別比、ゼロ間隔になるようにした方がよい)と間隔比率(期待指標含有量群別比、等しい間隔になるようにした方がよい)がある。基礎群(B)、対照群(C)、低投与量群(L)、高投与量群(H)に対する期待臓器重量群別比は1:1:1:1であり、理想的な期待等価的偏差写像関数群の間には有意な差異はない。期待指標含有量群別比は1:4:2:3であり、理想的な期待等級的偏差写像関数組の間には有意な差異。摂食戦略の写像関数映像関係には、各等価の偏差に有意な差異はないがあることが期待される。これは、期待臓器重量群別比が理想的な期待等価の偏差写像関数になっていることを示している。摂食戦略の写像関数映像関係には、各等級の偏差に有意な差異があることが期待される。これは、期待指標含有量群別比が理想的な期待等級の偏差写像関数になっていることを示している。
本発明の有利な効果として、本発明の明細書と図面の内容を利用した同等効果を持つ技術的変化は、すべて本発明の特許請求の範囲の保護対象となる。
Claims (9)
- コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法であって、前記の漢方薬配合の成分は、熟地黄、山茱萸、山薬、沢瀉、牡丹皮、茯苓、炮附子、及び肉桂を含む、ことを特徴とするコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記の成分の組成は、25-35 wt%の熟地黄、12-18 wt%の山茱萸、12-18 wt%の山薬、7-13 wt%の沢瀉、7-13 wt%の牡丹皮、7-13 wt%の茯苓、2-6 wt%の炮附子、2-6 wt%の肉桂である、ことを特徴とする請求項1に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記の成分の組成は、29.6 wt%の熟地黄、14.8 wt%の山茱萸、14.8 wt%の山薬、11.1 wt%の沢瀉、11.1 wt%の牡丹皮、11.1 wt%の茯苓、3.7 wt%の炮附子、3.7 wt%の肉桂である、ことを特徴とする請求項2に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記コレステロール改善とトリアシルグリセロール代謝とは、治療効果として受容体の体重過多、血糖異常、脂肪肝の程度異常、血脂またはコレステロールとトリアシルグリセロール異常を改善できることを指す、ことを特徴とする請求項1に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記コレステロール改善とトリアシルグリセロール代謝が前記漢方薬配合を通して、3-ヒドロキシ-3-メチルグルタリル補酵素Aおよびコレステリルエステル転送タンパク質の作用を同時に抑制して得られる効果である、ことを特徴とする請求項4に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記コレステロール改善とトリアシルグリセロール代謝が前記漢方薬配合を通して、非常に有意な改善過程において、高投与量がLDL-C減少に特に有効である、LDL-CはLDLR結合と細胞内取込み作用(endocytosis)により肝細胞に入る、ことを特徴とする請求項5に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記医薬化合物を毎日10-40グラムで必要とする個体に経口投与される、ことを特徴とする請求項1に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記医薬化合物の形態は、粉末、水抽出液、懸濁液、乳剤、シロップ、丸薬、トローチ、タブレット、カプセル剤、錠剤である、ことを特徴とする請求項1に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
- 前記医薬化合物に薬学上受容可能な担体がさらに含まれる、ことを特徴とする請求項1に記載のコレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108117608 | 2019-05-22 | ||
TW108117608 | 2019-05-22 | ||
TW108134506 | 2019-09-25 | ||
TW108134506A TWI816888B (zh) | 2019-05-22 | 2019-09-25 | 中藥複方在製備用於防治代謝症候群的藥物組合物中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020189838A true JP2020189838A (ja) | 2020-11-26 |
Family
ID=73442214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020089133A Pending JP2020189838A (ja) | 2019-05-22 | 2020-05-21 | コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11458181B2 (ja) |
JP (1) | JP2020189838A (ja) |
KR (1) | KR20200135739A (ja) |
CN (1) | CN111973697A (ja) |
CA (1) | CA3081078A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11458181B2 (en) * | 2019-05-22 | 2022-10-04 | Ying-Jih Chao Lee | Herbal formula used for preparing pharmaceutical composition for preventing and treating metabolic syndrome |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11839636B1 (en) * | 2022-07-27 | 2023-12-12 | Babry Oren | Pharmaceutical composition based on plant raw materials: #2.1 |
CN116421675B (zh) * | 2023-06-06 | 2024-05-07 | 浙江省中医院、浙江中医药大学附属第一医院(浙江省东方医院) | 一种用于治疗非酒精性脂肪性肝病的中药组合物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406796A (zh) * | 2011-11-03 | 2012-04-11 | 赵娜娜 | 一种治疗老年肥胖的药物 |
CN111973697A (zh) * | 2019-05-22 | 2020-11-24 | 吉岩科技有限公司 | 中药复方在制备用于防治代谢综合征的药物组合物中的用途 |
-
2020
- 2020-05-21 CN CN202010437455.5A patent/CN111973697A/zh active Pending
- 2020-05-21 JP JP2020089133A patent/JP2020189838A/ja active Pending
- 2020-05-21 CA CA3081078A patent/CA3081078A1/en not_active Abandoned
- 2020-05-22 US US16/881,006 patent/US11458181B2/en active Active
- 2020-05-22 KR KR1020200061462A patent/KR20200135739A/ko unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11458181B2 (en) * | 2019-05-22 | 2022-10-04 | Ying-Jih Chao Lee | Herbal formula used for preparing pharmaceutical composition for preventing and treating metabolic syndrome |
Also Published As
Publication number | Publication date |
---|---|
KR20200135739A (ko) | 2020-12-03 |
US11458181B2 (en) | 2022-10-04 |
CN111973697A (zh) | 2020-11-24 |
US20200368305A1 (en) | 2020-11-26 |
CA3081078A1 (en) | 2020-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230233472A1 (en) | Methods of preparing multiphase statin and omega-3 fatty acid soft capsule formulations | |
JP2020189838A (ja) | コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法 | |
JP5318108B2 (ja) | 脂質代謝を制御するための組成物 | |
JP2023100869A (ja) | 対象におけるマイトファジーを改善するための方法 | |
WO2010143053A1 (en) | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders | |
JP2020510678A (ja) | 対象におけるマイトファジーを改善するための方法 | |
CN105232525A (zh) | 一种降血脂药物组合物及其应用 | |
CN102058631B (zh) | 沙棘叶提取物制剂及其制备方法 | |
WO2021213232A1 (zh) | 一种中药组合物在制备治疗或预防高血脂症的药物中的应用 | |
DE102017105036A1 (de) | Mittel zur Anwendung bei der Behandlung der Dyslipidämie | |
US20100003351A1 (en) | Compositions comprising rhodiola rosea and methods of use thereof | |
WO2010002406A1 (en) | Compositions comprising rhodiola rosea and methods of use thereof | |
CN106349318A (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
CN101264121B (zh) | 一种降血脂保健品及制备方法 | |
CN107693598A (zh) | 一种降血脂的复方制剂及其制备方法 | |
CN100579567C (zh) | 一种中药制剂在制备预防冠心病药物中的用途 | |
Kim et al. | A 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Saccharum officinarum wax alcohols (Policosanol) on improvement of blood cholesterol | |
US20100303855A1 (en) | Method of reducing adverse effects of therapeutic agents for dyslipidemia | |
Murad et al. | Prevention is better than Cure: Apple and apricot | |
CN111588777A (zh) | 一种降血脂的枸杞组合物 | |
CN101797310B (zh) | 一种利湿破瘀且活血消瘀的降脂中药组合物 | |
CN110522791A (zh) | 甘草根异戊烯基黄酮在预防和治疗肥胖症中的应用 | |
CN104473957B (zh) | 一种用于降脂的中药单体组合物及其制剂 | |
CN117244032A (zh) | 一种通过调节免疫功能抗动脉粥样硬化的中药组合物及其制备方法 | |
CN113440517A (zh) | 利卡灵b在制备预防或/和治疗非酒精性脂肪肝病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230518 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230523 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240416 |